Catalyst Pharmaceuticals Inc (CPRX)

$17.59

+0.22

(+1.27%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $17.38
    $17.85
    $17.59
    downward going graph

    1.19%

    Downside

    Day's Volatility :2.63%

    Upside

    1.46%

    downward going graph
  • $11.55
    $17.99
    $17.59
    downward going graph

    34.34%

    Downside

    52 Weeks Volatility :35.8%

    Upside

    2.22%

    downward going graph

Returns

PeriodCatalyst Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
16.66%
6.5%
0.0%
6 Months
21.55%
7.1%
0.0%
1 Year
30.5%
9.8%
0.0%
3 Years
213.54%
14.2%
-20.2%

Highlights

Market Capitalization
2.1B
Book Value
$4.76
Earnings Per Share (EPS)
0.56
PE Ratio
31.27
PEG Ratio
0.0
Wall Street Target Price
27.29
Profit Margin
15.83%
Operating Margin TTM
27.54%
Return On Assets TTM
9.29%
Return On Equity TTM
14.55%
Revenue TTM
411.3M
Revenue Per Share TTM
3.77
Quarterly Revenue Growth YOY
15.4%
Gross Profit TTM
160.0M
EBITDA
114.0M
Diluted Eps TTM
0.56
Quarterly Earnings Growth YOY
-0.27
EPS Estimate Current Year
1.08
EPS Estimate Next Year
1.43
EPS Estimate Current Quarter
0.17
EPS Estimate Next Quarter
0.24

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Catalyst Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 55.14%

Current $17.59
Target $27.29

Company Financials

FY18Y/Y Change
Revenue
500.0K
-
Net Income
-34.0M
↑ 84.68%
Net Profit Margin
-6.8K%
-
FY19Y/Y Change
Revenue
102.3M
↑ 20361.27%
Net Income
31.9M
↓ 193.74%
Net Profit Margin
31.16%
↑ 6831.86%
FY20Y/Y Change
Revenue
119.1M
↑ 16.39%
Net Income
75.0M
↑ 135.24%
Net Profit Margin
62.97%
↑ 31.81%
FY21Y/Y Change
Revenue
140.8M
↑ 18.27%
Net Income
39.5M
↓ 47.35%
Net Profit Margin
28.03%
↓ 34.94%
FY22Y/Y Change
Revenue
214.2M
↑ 52.1%
Net Income
83.1M
↑ 110.42%
Net Profit Margin
38.79%
↑ 10.76%
FY23Y/Y Change
Revenue
398.2M
↑ 85.9%
Net Income
71.4M
↓ 14.05%
Net Profit Margin
17.93%
↓ 20.86%
Q4 FY22Q/Q Change
Revenue
60.8M
↑ 6.14%
Net Income
25.5M
↑ 11.97%
Net Profit Margin
41.92%
↑ 2.18%
Q1 FY23Q/Q Change
Revenue
85.4M
↑ 40.5%
Net Income
29.6M
↑ 16.08%
Net Profit Margin
34.64%
↓ 7.28%
Q2 FY23Q/Q Change
Revenue
99.6M
↑ 16.65%
Net Income
37.8M
↑ 27.71%
Net Profit Margin
37.92%
↑ 3.28%
Q3 FY23Q/Q Change
Revenue
102.7M
↑ 3.12%
Net Income
-30.8M
↓ 181.47%
Net Profit Margin
-29.96%
↓ 67.88%
Q4 FY23Q/Q Change
Revenue
110.6M
↑ 7.67%
Net Income
34.8M
↓ 213.26%
Net Profit Margin
31.51%
↑ 61.47%
Q1 FY24Q/Q Change
Revenue
98.5M
↓ 10.91%
Net Income
23.3M
↓ 33.2%
Net Profit Margin
23.63%
↓ 7.88%
FY18Y/Y Change
Total Assets
60.4M
↓ 29.21%
Total Liabilities
9.7M
↑ 118.51%
FY19Y/Y Change
Total Assets
112.4M
↑ 85.9%
Total Liabilities
24.7M
↑ 156.01%
FY20Y/Y Change
Total Assets
192.4M
↑ 71.17%
Total Liabilities
22.8M
↓ 8.04%
FY21Y/Y Change
Total Assets
237.8M
↑ 23.62%
Total Liabilities
31.0M
↑ 36.04%
FY22Y/Y Change
Total Assets
375.6M
↑ 57.97%
Total Liabilities
75.2M
↑ 142.95%
FY23Y/Y Change
Total Assets
471.9M
↑ 25.63%
Total Liabilities
84.0M
↑ 11.72%
Q4 FY22Q/Q Change
Total Assets
375.6M
↑ 12.76%
Total Liabilities
75.2M
↑ 19.24%
Q1 FY23Q/Q Change
Total Assets
407.2M
↑ 8.41%
Total Liabilities
73.6M
↓ 2.18%
Q2 FY23Q/Q Change
Total Assets
443.9M
↑ 9.0%
Total Liabilities
68.6M
↓ 6.75%
Q3 FY23Q/Q Change
Total Assets
413.2M
↓ 6.91%
Total Liabilities
64.7M
↓ 5.74%
Q4 FY23Q/Q Change
Total Assets
471.9M
↑ 14.2%
Total Liabilities
84.0M
↑ 29.94%
Q1 FY24Q/Q Change
Total Assets
646.7M
↑ 37.03%
Total Liabilities
85.3M
↑ 1.47%
FY18Y/Y Change
Operating Cash Flow
-25.7M
↑ 87.04%
Investing Cash Flow
-15.5M
↑ 392169.1%
Financing Cash Flow
293.1K
↓ 99.49%
FY19Y/Y Change
Operating Cash Flow
34.6M
↓ 234.65%
Investing Cash Flow
37.2M
↓ 339.76%
Financing Cash Flow
1.1M
↑ 280.82%
FY20Y/Y Change
Operating Cash Flow
45.0M
↑ 30.12%
Investing Cash Flow
-5.0M
↓ 113.46%
Financing Cash Flow
701.9K
↓ 37.12%
FY21Y/Y Change
Operating Cash Flow
60.4M
↑ 34.06%
Investing Cash Flow
-11.0M
↑ 119.92%
Financing Cash Flow
-8.1M
↓ 1260.08%
FY22Y/Y Change
Operating Cash Flow
116.0M
↑ 92.22%
Investing Cash Flow
9.2M
↓ 183.56%
Financing Cash Flow
1.7M
↓ 120.8%
Q1 FY23Q/Q Change
Operating Cash Flow
12.1M
↓ 69.88%
Investing Cash Flow
-162.4M
-
Financing Cash Flow
149.0K
↓ 93.39%

Technicals Summary

Sell

Neutral

Buy

Catalyst Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
15.19%
21.55%
30.5%
213.54%
254.49%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
31.27
31.27
0.0
1.08
0.15
0.09
NA
4.76
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
Buy
$2.1B
254.49%
31.27
15.83%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Catalyst Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 110.56M → 98.50M (in $), with an average decrease of 10.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 34.84M → 23.27M (in $), with an average decrease of 33.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 31.1%

Institutional Holdings

  • BlackRock Inc

    15.01%

  • Deerfield Management Co

    7.73%

  • State Street Corporation

    6.90%

  • Vanguard Group Inc

    6.76%

  • Dimensional Fund Advisors, Inc.

    2.32%

  • HHG PLC

    2.31%

Company Information

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso

Organization
Catalyst Pharmaceuticals Inc
Employees
167
CEO
Mr. Patrick J. McEnany
Industry
Health Technology

Discover More

FAQs